PRQR

1.63

0.61% -0.01

Vorhandelsmarkt: 1.62 -0.010 -0.61%

Proqr Therapeutics N V (PRQR)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

$1.64

Offen:

$1.63

24-Stunden-Volumen:

410.39K

Relative Volume:

0.78

Marktkapitalisierung:

$171.74M

Einnahmen:

$17.91M

Nettoeinkommen (Verlust:

$-47.66M

KGV:

-3.5856

EPS:

-0.4546

Netto-Cashflow:

$-62.63M

1W Leistung:

+10.14%

1M Leistung:

-4.68%

6M Leistung:

-31.51%

1J Leistung:

-9.44%

1-Tages-Spanne:

$1.59

$1.6973

1-Wochen-Bereich:

$1.43

$1.6973

52-Wochen-Spanne:

$1.33

$3.10

Proqr Therapeutics N V Stock (PRQR) Company Profile

Firmenname

Proqr Therapeutics N V

Sektor

Healthcare (1106)

Branche

Biotechnology (615)

Telefon

Adresse

Mitarbeiter

187

Twitter

@proqr

Nächster Verdiensttermin

2026-05-14

Neueste SEC-Einreichungen

PRQR's Discussions on Twitter

Compare PRQR vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PRQR Proqr Therapeutics N V	1.63	171.74M	17.91M	-47.66M	-62.63M	-0.4546
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-12	Fortgesetzt	Oppenheimer	Outperform
2025-04-29	Fortgesetzt	Cantor Fitzgerald	Overweight
2025-04-29	Eingeleitet	Evercore ISI	Outperform
2025-03-10	Hochstufung	Citigroup	Neutral → Buy
2025-01-10	Eingeleitet	Oppenheimer	Outperform
2024-10-29	Hochstufung	Raymond James	Outperform → Strong Buy
2023-11-08	Hochstufung	Chardan Capital Markets	Neutral → Buy
2023-03-30	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2022-12-22	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2022-02-14	Herabstufung	Citigroup	Buy → Neutral
2022-02-11	Herabstufung	Raymond James	Strong Buy → Mkt Perform
2022-02-11	Herabstufung	Stifel	Buy → Hold
2022-02-01	Eingeleitet	Raymond James	Strong Buy
2021-05-03	Eingeleitet	Stifel	Buy
2021-03-25	Bestätigt	Citigroup	Buy
2020-11-03	Fortgesetzt	Cantor Fitzgerald	Overweight
2019-03-12	Bestätigt	Chardan Capital Markets	Buy
2018-12-19	Eingeleitet	RBC Capital Mkts	Outperform
2018-11-15	Eingeleitet	Citigroup	Buy
2018-09-19	Eingeleitet	Evercore ISI	Outperform
2017-09-26	Bestätigt	JMP Securities	Mkt Outperform
2016-06-20	Eingeleitet	Chardan Capital Markets	Neutral
2014-10-15	Eingeleitet	Deutsche Bank	Buy
2014-10-13	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten

May 05, 2026

ProQR Sets June 2, 2026 Date for Annual General Meeting of Shareholders - The Globe and Mail

May 05, 2026

ProQR forms advisory board, partnership with Ginkgo as part of AI strategy - MSN

May 05, 2026

May 04, 2026

ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 - markets.businessinsider.com

May 04, 2026

ProQR Therapeutics NV expected to post a loss of 12 cents a shareEarnings Preview - TradingView

May 04, 2026

ProQR Therapeutics N : AGM 2026 POA Registered Shareholders - marketscreener.com

May 04, 2026

ProQR sets June 2 shareholder meeting, posts agenda documents online - Stock Titan

May 04, 2026

ProQR (PRQR) 2026 AGM to expand share capital, issuance and buyback powers - Stock Titan

May 04, 2026

May 03, 2026

MSN Money - MSN

May 03, 2026

May 01, 2026

ProQR Nominates Boehringer Ingelheim CMO Lykke Hinsch Gylvin to Board to Support Next Growth Phase - The Globe and Mail

May 01, 2026

Apr 30, 2026

ProQR nominates Boehringer Ingelheim executive to board - Investing.com UK

Apr 30, 2026

ProQR nominates Boehringer Ingelheim executive to board By Investing.com - Investing.com Australia

Apr 30, 2026

Boehringer exec tapped for ProQR (NASDAQ: PRQR) board nomination - Stock Titan

Apr 30, 2026

ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors - GlobeNewswire

Apr 30, 2026

Apr 29, 2026

ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Down 24.4% in April - MarketBeat

Apr 29, 2026

Apr 27, 2026

ProQR Therapeutics NV (MEX:PRQRN) Stock News, Headlines & Updates - GuruFocus

Apr 27, 2026

ProQR Therapeutics NV (MEX:PRQRN) Stock Price & 30 Year Financial Data - GuruFocus

Apr 27, 2026

Chardan Capital Maintains ProQR Therapeutics N.V. (PRQR) Buy Recommendation - MSN

Apr 27, 2026

Apr 26, 2026

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Apr 26, 2026

Apr 25, 2026

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat

Apr 25, 2026

Apr 22, 2026

ProQR Therapeutics NV (MEX:PRQRN) Short-term investments - GuruFocus

Apr 22, 2026

Apr 18, 2026

ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus

Apr 18, 2026

ProQR Therapeutics NV (MEX:PRQRN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus

Apr 18, 2026

Apr 16, 2026

Jobs Data: Can ProQR Therapeutics NV withstand a market correctionQuarterly Investment Review & AI Based Buy and Sell Signals - baoquankhu1.vn

Apr 13, 2026

Stock Analysis: Can ProQR Therapeutics NV outperform under higher oil prices2026 Short Interest & Precise Trade Entry Recommendations - baoquankhu1.vn

Apr 13, 2026

Volume Report: Is ProQR Therapeutics NV currently under institutional pressure2026 Gainers & Expert Verified Movement Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

If You Invested $1,000 in Proqr Therapeuti (PRQR) - Stock Titan

Apr 11, 2026

Apr 10, 2026

ProQR Therapeutics: Waiting On Proof As AX-0810 Data Approaches (NASDAQ:PRQR) - Seeking Alpha

Apr 10, 2026

Apr 09, 2026

PRQR: Chardan Capital Maintains Buy Rating with $4.00 Price Targ - GuruFocus

Apr 09, 2026

Proqr Therapeutics expands early-stage pipeline - BioWorld News

Apr 09, 2026

ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital - MarketBeat

Apr 09, 2026

ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter - Defense World

Apr 09, 2026

Aberdeen Group Boosts Stake in ProQR Therapeutics - National Today

Apr 09, 2026

Aberdeen Group plc Has $5.96 Million Holdings in ProQR Therapeutics N.V. $PRQR - MarketBeat

Apr 09, 2026

ProQR Details Axiomer Pipeline Expansion and New Liver and Genetic Disease Programs - The Globe and Mail

Apr 09, 2026

Apr 08, 2026

ProQR (PRQR) Partners with Ginkgo Bioworks to Boost AI-Driven Dr - GuruFocus

Apr 08, 2026

ProQR partners with Ginkgo on AI drug discovery platform By Investing.com - Investing.com Australia

Apr 08, 2026

ProQR updates RNA editing pipeline, targets biliary atresia By Investing.com - Investing.com Australia

Apr 08, 2026

ProQR Forms AI Advisory Board and Partners with Ginkgo Bioworks - Intellectia AI

Apr 08, 2026

ProQR updates RNA editing pipeline, targets biliary atresia - Investing.com

Apr 08, 2026

Pipeline expansion and cash runway into 2027 for ProQR (PRQR) - Stock Titan

Apr 08, 2026

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event - Weekly Voice

Apr 08, 2026